Stock MEDP MEDPACE HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Medpace Holdings, Inc.

Equities

MEDP

US58506Q1094

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
386.3 USD +0.17% Intraday chart for Medpace Holdings, Inc. -1.08% +26.04%
May. 29 Medpace Holdings Insider Sold Shares Worth $3,828,058, According to a Recent SEC Filing MT
May. 29 TD Cowen Starts Medpace Holdings With Buy Rating, $452 Price Target MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 3,010 4,952 7,782 6,589 9,405 11,943 - -
Enterprise Value (EV) 1 2,878 4,674 7,320 6,749 9,302 11,228 10,892 10,473
P/E ratio 31.5 x 36.3 x 45.2 x 29.2 x 34.5 x 34.4 x 29.5 x 25 x
Yield - - - - - - - -
Capitalization / Revenue 3.5 x 5.35 x 6.81 x 4.51 x 4.99 x 5.5 x 4.74 x 4.11 x
EV / Revenue 3.34 x 5.05 x 6.41 x 4.62 x 4.93 x 5.17 x 4.32 x 3.6 x
EV / EBITDA 19.2 x 24.9 x 32.8 x 21.9 x 25.7 x 26 x 21.5 x 17.6 x
EV / FCF 15.6 x 20.6 x 31.1 x 19.2 x 23.4 x 24.9 x 22 x 18.5 x
FCF Yield 6.39% 4.86% 3.21% 5.2% 4.26% 4.02% 4.55% 5.42%
Price to Book 4.35 x 6.51 x 8.61 x 18.5 x 17.5 x 12.8 x 9.58 x 7.3 x
Nbr of stocks (in thousands) 35,812 35,572 35,754 31,018 30,683 30,913 - -
Reference price 2 84.06 139.2 217.6 212.4 306.5 386.3 386.3 386.3
Announcement Date 2/24/20 2/15/21 2/14/22 2/13/23 2/12/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 861 925.9 1,142 1,460 1,886 2,170 2,522 2,906
EBITDA 1 149.6 187.8 223.1 308.1 362.5 432 506.8 593.5
EBIT 1 141.2 176.1 207.1 285.8 338.4 401.3 473.6 557.8
Operating Margin 16.4% 19.02% 18.13% 19.57% 17.94% 18.49% 18.78% 19.19%
Earnings before Tax (EBT) 1 124.8 168.5 201.9 282.9 335.7 426.2 503.9 591.7
Net income 1 100.4 145.4 181.8 245.4 282.8 360.1 421.3 495.1
Net margin 11.67% 15.7% 15.92% 16.81% 15% 16.59% 16.71% 17.04%
EPS 2 2.670 3.840 4.810 7.280 8.880 11.22 13.11 15.46
Free Cash Flow 1 184 227.3 235.1 351.2 396.7 451.6 495.3 567.5
FCF margin 21.37% 24.55% 20.58% 24.05% 21.04% 20.81% 19.64% 19.53%
FCF Conversion (EBITDA) 122.97% 121.08% 105.37% 113.98% 109.44% 104.52% 97.73% 95.62%
FCF Conversion (Net income) 183.14% 156.37% 129.26% 143.12% 140.28% 125.4% 117.57% 114.6%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/24/20 2/15/21 2/14/22 2/13/23 2/12/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 308.6 330.9 351.2 383.7 394.1 434.1 460.9 492.5 498.4 511 528.7 556.3 572.8 594 619.9
EBITDA 1 61.41 70.38 68.09 89.26 80.37 92.85 83.63 90.18 95.84 115.7 100.4 106.7 110.3 126.2 119.7
EBIT 1 57.22 66.11 63.38 84.31 74.47 87.44 77.66 83.86 89.41 109 94 100.5 103.5 116.7 112
Operating Margin 18.55% 19.98% 18.05% 21.97% 18.9% 20.14% 16.85% 17.03% 17.94% 21.33% 17.78% 18.06% 18.08% 19.65% 18.07%
Earnings before Tax (EBT) 1 55.92 65.32 62 81.89 73.64 86.03 75.74 83.2 90.71 112.8 98.61 105.8 109.8 124 118.4
Net income 1 50.03 61.31 49.36 66.03 68.67 72.89 61.07 70.55 78.3 102.6 81.23 87.16 90.42 103.7 98.94
Net margin 16.22% 18.53% 14.05% 17.21% 17.42% 16.79% 13.25% 14.32% 15.71% 20.07% 15.37% 15.67% 15.79% 17.45% 15.96%
EPS 2 1.320 1.690 1.460 2.050 2.120 2.270 1.930 2.220 2.460 3.200 2.518 2.706 2.812 3.253 3.075
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 2/14/22 4/25/22 7/25/22 10/24/22 2/13/23 4/24/23 7/24/23 10/23/23 2/12/24 4/22/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - 161 - - - -
Net Cash position 1 132 278 461 - 103 715 1,051 1,470
Leverage (Debt/EBITDA) - - - 0.5213 x - - - -
Free Cash Flow 1 184 227 235 351 397 452 495 567
ROE (net income / shareholders' equity) 17.2% 19.9% 20.7% 36.6% 59.8% 46.2% 37.1% 34.7%
ROA (Net income/ Total Assets) 10.7% - 11.9% 16.3% 18.8% 18.3% 16.7% 15.6%
Assets 1 935.7 - 1,525 1,506 1,505 1,964 2,529 3,167
Book Value Per Share 2 19.30 21.40 25.30 11.50 17.60 30.20 40.30 52.90
Cash Flow per Share 2 5.370 6.860 6.990 11.50 13.60 16.70 15.80 18.00
Capex 1 17.9 31.3 28.3 36.9 36.6 43.6 50.9 55
Capex / Sales 2.08% 3.38% 2.47% 2.53% 1.94% 2.01% 2.02% 1.89%
Announcement Date 2/24/20 2/15/21 2/14/22 2/13/23 2/12/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Medpace Holdings, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
386.3 USD
Average target price
428.2 USD
Spread / Average Target
+10.85%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.63B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
LONZA GROUP AG Stock Lonza Group AG
+37.52% 38.82B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-11.83% 10.74B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. MEDP Stock
  4. Financials Medpace Holdings, Inc.